Metformin Hydrochloride Milpharm (Metformin)

Metformin reduces hepatic glucose production by activating AMP‑activated protein kinase (AMPK) and inhibits gluconeogenesis. It also improves peripheral insulin sensitivity, enhancing glucose uptake in muscle and adipose tissue, thereby lowering circulating blood glucose without stimulating insulin secretion.

The dose of Metformin Hydrochloride Milpharm is individualized. A qualified prescriber determines the appropriate strength, frequency and titration schedule based on the patient’s renal function, glycaemic targets and overall clinical condition.

Safety data in pregnancy are limited, and metformin is generally avoided unless the potential benefit outweighs the risk. It is excreted in breast milk, so breastfeeding mothers should consult their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin is a first‑line biguanide that lowers glucose without causing hypoglycaemia when used alone, unlike sulfonylureas which stimulate insulin release. It also promotes modest weight loss, whereas insulin therapy can lead to weight gain. Its safety profile and cardiovascular benefits make it a preferred initial therapy for many patients.

Store the product at ambient temperature, below 25 °C, in the original packaging. Protect it from moisture, direct sunlight and excessive heat. Do not use if the tablet integrity is compromised or if the expiry date has passed.

Metformin Hydrochloride Milpharm is taken orally, usually with meals to minimise gastrointestinal upset. Tablets should be swallowed whole with a full glass of water; they are not intended for crushing or dissolving unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, or in those consuming excessive alcohol. Severe skin reactions such as Stevens‑Johnson syndrome are also rare but require immediate medical attention.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and in those with severe hepatic disease. Caution is also advised for patients with a history of alcohol abuse.